Bioprocessing News and Research

RSS

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

New Brunswick Scientific, Pall partner to develop new disposable bioreactor systems

New Brunswick Scientific, an Eppendorf Company, and Pall Corporation today announced a joint product development and marketing agreement to create and supply new disposable bioreactor systems.

From Pall Corporation 14 Jun 2010

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen Corporation today reported results for the fourth quarter and fiscal year 2010, ended March 31, 2010. Total revenue for the year was $20,971,000 compared to total revenue of $29,362,000 for fiscal year 2009 ended March 31, 2009.

9 Jun 2010

A new generation of cereal based products for patients with celiac disease

A wide range of gluten free cereals have been studies in detail as part of the HEALTHGRAIN project of the European Union, and their impact on product quality has been assessed. Enzyme technology, bioprocessing as well as high-pressure processing technology have been successfully applied to improve the quality, safety and nutritional attributes of gluten free cereal products.

10 May 2010

Enzyme technology developed to improve quality, safety and nutritional attributes of oat based foods

Oats is a highly nutritious cereal, which can be tolerated by large number of celiac patients. A range of commercial oat flours as well as specific oat flours produced from single varieties have been evaluated for their suitability for bread-baking. Enzyme technology, bioprocessing as well as high-pressure processing technology have been successfully applied to improve the quality, safety and nutritional attributes of oat based foods.

5 May 2010

Repligen expects total revenue of $21.0M for fiscal year 2010

Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.

16 Apr 2010

BIO pleased with Court's dismissal of claims over patenting gene-based inventions

“As explained in the ruling yesterday, the District Court's determination is only a preliminary step in the legal process that does not affect how the U.S. Patent and Trademark Office (PTO) evaluates patent applications relating to DNA-based inventions.”

31 Mar 2010

Public and private sectors fund bioprocessing research for drug development

The search for new medicines will receive a £10M boost this week as the public and private sectors unite to fund bioprocessing research. The money is now available for scientists to apply for from the Bioprocessing Research Industry Club (BRIC) which aims to bring academics and industry together to find ways of delivering new medicines from biological materials more quickly and effectively.

25 Mar 2010

Genes allowing opium poppy to make codeine and morphine discovered

Researchers at the University of Calgary have discovered the unique genes that allow the opium poppy to make codeine and morphine, thus opening doors to alternate methods of producing these effective painkillers either by manufacturing them in a lab or controlling the production of these compounds in the plant.

18 Mar 2010

Repligen acquires BioFlash

Repligen Corporation announced today that it has acquired the assets of BioFlash Partners, LLC, (BioFlash) including a technology platform for the production of pre-packed, "plug and play" chromatography columns. This patented technology enables economical production of chromatography columns in a format that is ready for use in the production of a broad range of biopharmaceuticals including monoclonal antibodies, vaccines and recombinant proteins.

4 Mar 2010

Nominations accepted for 2010 George Washington Carver Award

The third annual George Washington Carver Award will recognize significant contributions by an individual to the field of industrial biotechnology, including applications in biological engineering, environmental science, biorefining and biobased products. The Biotechnology Industry Organization today announced that it is accepting nominations for the 2010 George Washington Carver Award, which will be presented at the 2010 World Congress on Industrial Biotechnology and Bioprocessing, June 27-30, 2009 in Washington, D.C.

24 Feb 2010

Epeius Biotechnologies completes construction of VPU to manufacture targeted genetic medicines

Epeius Biotechnologies (www.epeiusbiotech.com) announces the completion of the design engineering and construction phase of a state-of-the-art Vector Production Unit (VPU) for the commercial manufacturing of its advanced targeted genetic medicines. In accordance with an FDA Critical Path initiative, which encourages innovation and the implementation of new technological advances in GMP, CMC, aseptic processing, and quality control, the Epeius VPU is poised to launch the large-scale production of targeted genetic medicine into the 21st century.

18 Feb 2010

BAC adds affinity resin for AAT purification to GE Healthcare’s range of custom designed media

BAC BV, the leading provider of antibody-based affinity purification technology, has extended its collaboration with GE Healthcare with the addition of a new bioprocess affinity chromatography ligand to GE Healthcare’s range of custom designed media. The latest addition to the range is an affinity resin for the purification of alpha-1 antitrypsin (AAT) from blood plasma, recombinant cell culture or transgenic sources. The new resin has been developed as part of GE Healthcare’s Custom Designed Media (CDM) programme and provides a new solution for AAT purification in the biopharmaceutical industry.

17 Feb 2010

Repligen receives USPTO Notice of Allowance for patent covering a recombinant form of Protein A

Repligen Corporation announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent covering a recombinant form of Protein A which is identical in structure to the commercial form of Protein A from Staphylococcus aureus which is used in the production of many of the world's approved monoclonal antibodies. The patent, which will remain in force until 2028, covers a new Repligen proprietary product which is now available in commercial quantities.

4 Feb 2010

VTT Innovation Program on food, nutrition and eating pattern

The objective of this roadmap was to feature the drivers, needs and future potential for various actors involved in the food production and distribution chain, but also for actors developing services offering communication and motivation tools for consumers who wish to improve their nutrition.

23 Dec 2009

Emergent BioSolutions acquires 55,000 square foot manufacturing facility from MdBio Foundation

Emergent BioSolutions Inc. announced today that it has completed the acquisition of a 55,000 square foot manufacturing facility from MdBio Foundation and the land on which the facility stands from the City of Baltimore for a total purchase price of $8.2 million. The facility, located within the City of Baltimore, Maryland, previously operated as a Food and Drug Administration (FDA) licensed facility used by an experienced contract manufacturing organization (CMO) to produce a number of FDA approved products.

13 Nov 2009

Butterfly experiment in space

When NASA's space shuttle Atlantis launches for the International Space Station on Nov. 16 it will carry a University of Colorado at Boulder butterfly experiment that will be monitored by thousands of K-12 students across the nation.

11 Nov 2009

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial.

22 Oct 2009

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare.

20 Oct 2009

Intrexon purchases assets and operations of Avalon Pharmaceutical

Intrexon Corporation, a privately held life sciences company focused on modular DNA control systems for biotherapeutics and other industry sectors, today announced the purchase of assets and operations of Avalon Pharmaceutical, Inc., a wholly-owned subsidiary of Clinical Data, Inc.

1 Sep 2009